News >

Benefit of Extended Adjuvant Endocrine Therapy Remains Unknown

Angelica Welch
Published: Monday, Oct 29, 2018

Melanie Majure, MD
Melanie Majure, MD
Patients with hormone receptor (HR)-positive breast cancer generally have a good prognosis, said Melanie Majure, MD. However, more work needs to be done since greater than 50% of patients’ disease recurs after 5 years, she added.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication